Background Urinary proteomics has been extensively applied to investigate renal diseases including acute kidney injury (AKI), chronic kidney disease (CKD), IgA nephropathy (IgAN) and diabetic CKD. However, differential urinary proteome studies have not been reported for multiple diseases. The present study was aimed to explore early clinical diagnosis biomarkers for patients with AKI, AKI+CKD, diabetic CKD, non-diabetic CKD with IgAN and non-diabetic CKD without IgAN. Methods Differentially expressed proteins (DEPs) were screened by iTRAQ labeling and 2-D LC-MS/MS. Bioinformatics analysis was performed by subsequent GO enrichment and KEGG pathway analysis. DEPs were authenticated by ELISA assay. Results 156, 156, 286, 187 and 184 differentially abundant proteins were identified in patients with AKI, AKI+CKD, diabetic CKD, and non-diabetic CKD with or without IgAN. Comparative analysis indicated that 34, 35 and 17 unique DEPs were found in AKI, AKI+CKD and CKD samples, respectively. 91 and 14 specific DEPs were screened out in diabetic CKD and non-diabetic CKD. In comparison with Non-diabetic CKD with IgAN (38 DEPs), 47 unique urinary proteins were found in Non-diabetic CKD without IgAN. Among these DEPs, urinary SAA1 and HGFAC were only unregulated in AKI and Non-diabetic CKD without IgAN implying that they might be employed as the potential indicators of the two diseases. C5, APOC1 and Reg3A upregulation was not exclusively expressed in each disease which suggested that they could not be used for biomarker to distinguish one disease from the other. Conclusion Collectively, this research contributes to the urinary biomarker discovery from multiple renal diseases. component 5; APOC1, Since apolipoprotein C-I; Reg3A, Regenerating islet-derived protein 3 alpha.
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Background Kidney disease includes acute kidney injury (AKI) and chronic kidney disease (CKD), often resulting in renal failure, especially among hospitalised patients. Causes of kidney disease are numerous and complex, including deposition of immunoglobulin A (IgA) antibodies in the glomerulus, termed IgA nephropathy (1) , diabetes mellitus leading to diabetic nephropathy (DN) (2) , and high blood pressure-initiated hypertensive nephropathy (3). To date, ~400 different rare renal diseases have been reported. Therefore, it is very important to identify reliable biomarkers that facilitate early diagnosis of kidney diseases and help distinguish one type of disease from another.
The urinary proteome consists of blood and renal-derived proteins that can reflect systemic and renal disorders. Urinary proteomics approaches have been widely used to differentiate disease types and stages, and to assist the discovery of diagnostic biomarkers, especially for kidney disease. AKI involves an abrupt loss of kidney function that develops within 7 days, and ~5-10% of AKI patients can progress into CKD, and even end-stage kidney disease (ESRD), depending on the cause (4, 5) .
Clinically, AKI is often diagnosed based on the elevation of blood urea nitrogen and creatinine, or the amount of urine per 24 h period. Recently, numerous novel AKI biomarkers, such as neutrophil gelatinase-associated lipocalin (NGAL) (6) , kidney injury molecule 1 (KIM-1) (7) interleukin 18 (IL-18) (8), liver-type fatty acid-binding protein (L-FABP) (9) and activin A (10) , have been identified in urine and found to contribute to early detection, differential diagnosis, and prognosis for AKI. CKD, as a common type of renal disease, is characterised by a gradual loss of kidney function over a period of months or years, and mainly includes DN, non-diabetic nephropathy (NDN) and other types of nephropathy. Reduction in estimated glomerular filtration rate (eGFR) is regarded as the best predictor of CKD, but this is only effective during the latter stages of renal disease (11) . Cystatin C and creatinine are protein biomarkers for CKD, and cystatin C may improve eGFR in the progression of CKD (12) . Evidence suggests that urinary 8 -hydroxyl -2′deoxyguanosine (8-OHdG) (13) , transferrin (14) , type IV collagen (15) , NGAL (16) , and monocyte chemoattractant protein-1 (MCP-1) (17) can be used as biomarkers to predict patients with DN.
IgA nephropathy (IgAN), characterised by deposition of IgA antibodies in the glomerulus, is the most common form of glomerulonephritis throughout the world (18) . Based on nano-liquid chromatography-tandem mass spectrometry (LC-MS/MS), 2D-electrophoresis-matrix-assisted laser desorption ionisation-time-of-flight/timeof-flight (2DE-MALDI-TOF-TOF) mass spectrometry (MS) and enzyme-linked immunosorbent assay (ELISA) analytical techniques, numerous studies have identified many noninvasive diagnostic markers in urinary excretions from relevant proteins in IgAN, including GP2, protocadherin (19) , albumin fragments, LG3 (20) and others. Although a growing number of urine protein markers for kidney disease have been identified using advanced biotechnological methods, only a few urine protein biomarkers have been validated and used for clinical purposes. Additionally, case-crossover studies among multiple renal diseases to identify specific urinary protein markers that can accurately distinguish between different kidney diseases have not been reported.
Herein, based on isobaric tag for relative and absolute quantitation (iTRAQ) labelling and LC-MS/MS, we identified differentially expressed proteins (DEPs) in urine from patients with AKI, AKI+CKD, diabetic CKD, and non-diabetic CKD with or without IgAN. We subsequently performed Gene Ontology, GO term, and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analyses using the identified DEPs. Finally, we identified specific DEPs in each of the five types of kidney diseases. In summary, we identified several novel urinary protein biomarkers that can distinguish and assist classification of multiple kidney diseases.
Methods

Subjects
A total of 300 urine samples were obtained for urinary proteomic profiling from healthy volunteers (n = 50) and patients with early AKI (n = 50), AKI with chronic kidney disease (AKI+CKD; n = 50), diabetic CKD (n = 50), non-diabetic CKD with IgAN (n = 50), and non-diabetic CKD without IgAN (n = 50). Inclusion criteria for early AKI (Stage I) were an increase in blood creatinine by 26.2 μmol/l, or 1.5-1.9fold in 48 h and urine volume less than 0.5 ml/Kg/h for more than 6 h (less than 12 h). Inclusion criteria for early CKD were based on the GFR which ranged from 45 ml/min/1.73 m 2 to 59 ml/min/1.73 m 2 . AKI+CKD patients were judged by clinical examination index as described above. Diabetic CKD, non-diabetic CKD with IgAN (n = 50) and non-diabetic CKD without IgAN patients were categorised by diabetic symptoms or IgAN from CKD patients. This study was approved by the Human Medical Ethics Committee of Zhejiang Provincial People's Hospital.
Urine collection, urinary protein extraction and digestion
In brief, void mid-stream morning urine samples (50 ml for kidney disease samples and 150 ml for the control group) were collected in sterile containers and divided 6 into 10 ml/tube,1 ml protease inhibitor was added, and samples were centrifuged at 2000 ´g for 20 min at 4°C. Supernatants from the same illness were removed, combined, and stored at -80°C for subsequent experiments. Urinary proteins were isolated using the trichloroacetic acid (TCA)-acetone precipitation method, and the concentration of total urinary protein was measured using a bicinchroninic acid (BCA) Protein Assay Kit (23225, Thermo Fisher Scientific, MA, US). Urinary proteins were quantified and the quality was assessed using Bradford assays and sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). Based on the quantitation results, 100 μg urinary protein was diluted 10-fold using 0.5 M tetraethylammonium bromide (TEAB) containing 0.1% SDS and digested with trypsin (50:1 protein/trypsin w/w; Promega, Madison, WI) at 37°C for 3 h. Peptides were cleaned and redissolved in TEAB/water (1:1 v/v).
iTRAQ labelling
Peptide concentrations were measured using a BCA kit and sample volumes were adjusted to 15 μl total volume containing 25 μg peptides using 0.5 M TEAB. Peptides were labelled using 8-plex iTRAQ reagent according to the manufacturer's protocol (4381663, Sigma, Germany). Briefly, peptides were labelled with iTRAQ reagents for 1 h at room temperature, and iTRAQ-113, 114, 115, 116, 117 and 118 were used to label peptide samples from patients with AKI, AKI+CKD, diabetic CKD, non-diabetic CKD with IgAN and N=non-diabetic CKD without IgAN, respectively. Labelled samples were mixed as a pool and dried in a vacuum concentrator. 
Mass spectrometric analysis
Data analysis
MS data were searched against the UniProt human database using Proteome Discoverer software version 1.4 (Thermo Scientific). All peptides were validated with a false discovery rate (FDR) <0.01%. Parameters for qualitative and quantitative analysis of urinary peptide samples were set according to general preferences.
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Trypsin was used with one missed cleavage allowed and Carbamidomethyl was employed as a fixed modification. The tolerance of peptides and fragments were set to ± 20 ppm and 0.1 Da, respectively. The integration window tolerance was set as 20 ppm according to the Most Confident Centroid method. Other parameters such as Scan Event Filters were set as follows: Mass Analyzer = FTMS, MS Order = MS2, Activation Type = HCD. Protein ratios were calculated as the median of only unique peptides for each protein, and normalised by the median protein ratio. A foldchange of >1.2 was applied as a cut-off for identifying DEPs from different kidney diseases. 
Gene ontology enrichment and pathway analysis
ELISA assay
Concentrations of urinary proteins SAA1, C5, HGFAC, APOC1 and Reg3A were measured in samples from each of the five types of kidney disease (n = 30 per disease) according to the manufacturer's instructions. ELISA kits for SAA1 (DY3019-9 05), HGFAC (DY5940-05) and Reg3A (DY1514) were purchased from R&D (Minnesota, US). APOC1and C5 ELISA kits were obtained from Abcam (ab108808) and BD (557965), respectively.
Statistical analysis
All data are presented as mean ± standard error of the mean (SEM) and were analysed using SPSS (Chicago, US) and Graphpad prism software (CA, US).
Statistical comparisons among groups were performed using one-way analysis of variance (ANOVA) or Student's t-tests, and p <0.05 was considered statistically significant.
Results
Identification of DEPs in urine from kidney disease patients
In order to the identify DEPs in urine from patients with multiple kidney diseases, the urinary proteomes of patients with AKI, AKI+CKD, diabetic CKD, non-diabetic CKD with IgAN, non-diabetic CKD without IgAN, and healthy volunteers were labelled using iTRAQ reagents (Figure 2 Cluster and volcano plot analyses of urinary DEPs identified in the five renal diseases). Cluster analysis of AKI and controls revealed that APOL1, protein S and rheumatoid factor were increased 3-fold, while histone H4, neuroblast differentiation-associated protein AHNAK and calcitonin were own-regulated by more than 4-fold (Figure 2A and Table S1, first image). Among (Figure 2B, Figure S1B-S4B ). Figure 4A , single-organism process, protein binding, multicellular organismal process and developmental process were the main biological functions related to urinary DEPs in AKI patients (Figure 4A) .
Gene ontology annotation of targeted DEPs
Meanwhile, DEPs in AKI+CKD played an important role in developmental processes, system development and biological adhesion (Figure 4B) . Among DEPs mediating biological functions, regulation of response to external stimuli, enzyme inhibitor activity, and endopeptidase regulator/inhibitor activity were the most obvious in diabetic CKD patients compared with the control group (Figure 4C) . Multicellular organismal process, developmental process, and tissue development are predominant in non-diabetic CKD with IgAN, and single-multicellular organism process, multicellular organismal development, and metal ion binding are the main biological processes in non-diabetic CKD without IgAN patients (Figure 4D, E) .
These results suggest that the biological functions regulated by DEPs in these renal diseases are diverse and complex.
KEGG pathway analysis of identified DEPs in different kidney diseases
Further analysis of biological pathways using the KEGG database revealed 6, 13, 12, 10 and 14 signalling pathways that were enriched among the five kidney diseases (Figure 5D, E) . Thus, bioinformatics analysis of KEGG pathways revealed commonalities as well as process-specific differences among these renal diseases. Importantly, these results imply that some unique signalling pathway could be targeted for the development of therapies for different renal diseases. (Figure 6A and Table 1 ). Further biological function analysis indicated that 22 specific DEPs in AKI were closely related to proliferation, apoptosis, survival, inflammation, repair and migration. For example, SAA1 is associated with proliferation, inflammation and migration, while SHBG is involved in progression of proliferation, apoptosis and survival ( Table 2) . Using this method, 12
Biomarker discovery and verification of unique
unique DEPs including IGHG1 and PAPPA2 were identified in the AKI+CKD group (Table 3) . In contrast to AKI and AKI+CKD groups, 12 urinary DEPs from CKD patients participate in the biological processes mentioned above ( Table 4) . CKD includes diabetic CKD and non-diabetic CKD patients, and 44 and 6 specific urinary protein markers were identified in these group, respectively ( for validation to support our present work. In ELISA assays, an increase in SAA1 was only observed in urine from AKI patients, suggesting that SAA1 could be used as an indicator of AKI disease (Figure 6B) . C5 upregulation was observed in all five kidney diseases, implying it is a universal protein marker for all five diseases ( Figure 6C) . In samples from patients with non-diabetic CKD without IgAN, HGFAC levels were significantly enhanced compared with other groups, which indicates that HGFAC is a potential biomarker for early diagnosis of non-diabetic CKD without IgAN (Figure 6D) . Based on the results shown in Figure 6E , we speculated that detection of APOC1, which was upregulated in all renal diseases except diabetic CKD, could be used to distinguish diabetic CKD from other kidney diseases (Figure 6E) . Enhancement in Reg3A abundance was observed in both AKI and AKI+CKD groups, which suggests that Reg3A differs significantly between AKI and CKD patients ( Figure 6F) . Importantly, these results were consistent with our MS data.
Discussion 15
The urinary proteome consists of more than 1500 proteins that accurately reflect renal physiology and pathophysiology, as well as kidney dysfunction (21, 22) . Given that urine collection is non-invasive and facile, urinary proteomics is growing in popularity for kidney disease diagnostics (23) . Currently, MS-based proteomic analysis the dominant tool for urinary protein biomarker discovery in kidney disease (24) . However, at present there are no completely reliable indicators to specifically discriminate between diverse types of renal disease, due to the complexity of urine and renal pathology. In our present study, we discovered specific DEPs in patients with AKI, AKI+CKD, diabetic CKD, and non-diabetic CKD with or without IgAN analysis revealed major differences in BP, CC, and MF categories of DEPs, but also indicated some common molecular functions and signalling transduction pathways among the five diseases. Our findings could assist a possible strategy to better understand differences between the five kidney diseases by studying the specific molecular functions and signalling pathways involved in each disease. SAA1, an inflammatory protein mainly produced by hepatocytes, is upregulated by factors that enhance inflammatory cytokines (30) . In blood circulation, it is closely related to high-density lipoprotein (HDL) and is of great importance in liver metabolism, responses to infection, and renal cell carcinoma (31) (32) (33) . HGFAC is a serine protease and key determinant in tissue injury and the progression of renal cell carcinoma (34, 35) . Detailed analysis and filtering of synchronously altered DEPs identified SAA1 and HGFAC as highly expressed in patients with AKI and nondiabetic CKD without IgAN, implying that detection of urinary SAA1 and HGFAC may help to distinguish these two diseases in a clinical setting. C5, a member of the complement system, can moderate lipid metabolism and reduce fibrosis in DN (36) .
C5 activation is also observed in patients with lupus nephritis and renal cell carcinoma, which suggests that activated C5 is widespread in kidney diseases (37, 38) . Since apoCI, encoded by the apoc1 gene, is expressed primarily in the liver, its plasma concentration is associated with an increased risk of developing DN, and it acts as a key factor in the pathogenesis of glomerulosclerosis (39, 40) . Our results further confirmed that urinary C5 is a specific marker of multiple kidney diseases.
Nevertheless, urinary apoCI could be used for early diagnosis for various kidney diseases except diabetic CKD. Reg3A is mainly increased during pancreatic inflammation and liver carcinogenesis, and during mammalian urinary tract infection, both Reg3 gamma and HIP/PAP are induced, implying that RegA3 might be implicated in inflammation responses during renal disease (41) . Based on our findings, we concluded that RegA3 upregulation is associated with AKI and AKI+CKD patients, but not CKD patients, regardless of diabetic CKD or non-diabetic CKD status, and with or without IgAN.
Conclusions
In summary, we performed urinary proteomics analysis of multiple kidney diseases for the first time, and identified numerous urinary proteins that are common to five different types of disease, as well as several unique protein markers for each disease. Importantly, identified and validate SAA1, HGFAC, C5, APOC1 and RegA3 as common or specific biomarkers for different kidney diseases. This work provides fundamental biological information for multiple kidney diseases, and could accelerate the development of this field in the future. Figure S1-S4.docx Table S1-S13.doc
Abbreviations
